JMP Securities Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst David Turkaly maintains a Market Outperform rating on Integra Lifesciences (NASDAQ:IART) but lowers the price target from $40 to $35.
July 30, 2024 | 3:23 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JMP Securities analyst David Turkaly maintains a Market Outperform rating on Integra Lifesciences but lowers the price target from $40 to $35.
The Market Outperform rating suggests continued confidence in the stock's performance, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100